bioMérieux – Q3 2021 Results

  • Organic growth of 12.1% at constant exchange rates and scope of consolidation over the first nine months of the year:
    • €2,452 million in sales
    • Up 8.2% as reported
  • Q3 sales organic growth at 11.6%, significantly above expectations due to a strong upturn in US respiratory panels demand, combined with a solid momentum in all other applications
  • Upward revision of 2021 outlook: in the light of Q3 higher-than-expected respiratory multiplexing testing demand,  bioMérieux  is raising its FY'21 outlook. Full year  sales  are now expected to grow between 4% and 7% (previously: at neutral to mid-single digit rate), at constant exchange rates and scope of consolidation. Contributive operating income before non-recurring items should be above €700 million (previously: in line with 2020) at current exchange rates.

Contact us